

28 November 2022

APPENDIX 3G

Aroa Biosurgery Limited (ASX:ARX, 'Aroa' or the 'Company') advises that it has issued 1,867,305 options to acquire shares (the 'Share Options') in the Company to CEO, Brian Ward on the terms of the Aroa Biosurgery Share Option Plan. The Share Options represent Mr. Ward's 2022 LTI as approved by the Company's shareholders at its 2022 Annual General Meeting. Details relating to the Share Options and key terms of the Aroa Biosurgery Share Option Plan were outlined in the Notice of Meeting. The Company operates the Aroa Biosurgery Share Option Plan as part of its remuneration policy and considers the alignment of employees to long-term value delivery a critical success factor for the Company.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA's products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com

Contacts

Investor

Simon Hinsley
Investor Relations
shinsley@aroabio.com
+ 61 401 809 653

Media

Australia
Matthew Wright
matt@nwrcommunications.com.au
+61 451 896 420

New Zealand
Sarah Tora
sarah.tora@aroabio.com
+64 21 531 043